Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Dexlansoprazole | hsa00052 | Galactose metabolism | 1.06E-03 | 2 | P06280, O43451 | GLA, MGAM | More | | Dexlansoprazole | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Dexlansoprazole | hsa00220 | Arginine biosynthesis | 1.21E-02 | 1 | P15104 | GLUL | More | | Dexlansoprazole | hsa00230 | Purine metabolism | 1.56E-02 | 3 | Q7LG56, P51828, Q9Y227 | RRM2B, ADCY7, ENTPD4 | More | | Dexlansoprazole | hsa00240 | Pyrimidine metabolism | 1.51E-03 | 4 | Q7LG56, Q9Y227, P21589, P04183 | RRM2B, ENTPD4, NT5E, TK1 | More | | Dexlansoprazole | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Dexlansoprazole | hsa00310 | Lysine degradation | 2.59E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Dexlansoprazole | hsa00330 | Arginine and proline metabolism | 4.86E-02 | 1 | P17707 | AMD1 | More | | Dexlansoprazole | hsa00480 | Glutathione metabolism | 3.29E-04 | 4 | Q9UJ14, Q16772, P09211, P30041 | GGTL3, GSTA3, GSTP1, PRDX6 | More | | Dexlansoprazole | hsa00500 | Starch and sucrose metabolism | 2.33E-08 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Dexlansoprazole | hsa00512 | Mucin type O-glycan biosynthesis | 4.86E-02 | 2 | O95395, Q9NY28 | GCNT3, GALNT8 | More | | Dexlansoprazole | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | | Dexlansoprazole | hsa00564 | Glycerophospholipid metabolism | 5.68E-03 | 3 | Q6P1A2, P23743, Q8TCT1 | MBOAT5, DGKA, PHOSPHO1 | More | | Dexlansoprazole | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Dexlansoprazole | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Dexlansoprazole | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.19E-05 | 2 | P40925, P15104 | MDH1, GLUL | More | | Dexlansoprazole | hsa00640 | Propanoate metabolism | 3.83E-02 | 2 | Q02252, Q9P2R7 | ALDH6A1, SUCLA2 | More | | Dexlansoprazole | hsa00730 | Thiamine metabolism | 1.87E-06 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Dexlansoprazole | hsa00790 | Folate biosynthesis | 1.04E-02 | 3 | Q92820, P05186, P42330 | GGH, ALPL, AKR1C3 | More | | Dexlansoprazole | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Dexlansoprazole | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.17E-02 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | | Dexlansoprazole | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.28E-06 | 4 | Q16772, P78417, P09211, P11712 | GSTA3, GSTO1, GSTP1, CYP2C9 | More | | Dexlansoprazole | hsa00982 | Drug metabolism - cytochrome P450 | 1.58E-05 | 4 | P11712, Q16772, P09211, P78417 | CYP2C9, GSTA3, GSTP1, GSTO1 | More | | Dexlansoprazole | hsa00983 | Drug metabolism - other enzymes | 1.66E-04 | 5 | P04183, P32320, P05164, Q16772, P09211 | TK1, CDA, MPO, GSTA3, GSTP1 | More | | Dexlansoprazole | hsa01100 | Metabolic pathways | 3.55E-03 | 34 | Q9NR34, P35790, P05089, Q16772, P09211, Q9UJ14, P30041, P32320, P22748, P40926, P55809, P06280, Q16875, O43286, O43451, Q7KZN9, P05186, P24666, P15121, Q9HCC0, P33121, Q9UHK6, Q86VZ5, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737, Q9BQB6 | MAN1C1, CHKA, ARG1, GSTA3, GSTP1, GGTL3, PRDX6, CDA, CA4, MDH2, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, COX15, ALPL, ACP1, AKR1B1, MCCC2, ACSL1, AMACR, SGMS1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL, VKORC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9NR34 | MAN1C1 | Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC | -0.716 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | P35790 | CHKA | Choline kinase alpha | -0.717 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P05089 | ARG1 | Arginase-1 | 0.702 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | Q16772 | GSTA3 | Glutathione S-transferase A3 | -0.793 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | P09211 | GSTP1 | Glutathione S-transferase P | 0.712 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | Q9UJ14 | GGTL3 | Glutathione hydrolase 7 | 0.748 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | P30041 | PRDX6 | Peroxiredoxin-6 | 0.75 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P32320 | CDA | Cytidine deaminase | 0.701 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P22748 | CA4 | Carbonic anhydrase 4 | 0.767 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | P40926 | MDH2 | Malate dehydrogenase, mitochondrial | 0.81 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P55809 | OXCT1 | Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial | -0.746 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P06280 | GLA | Alpha-galactosidase A | 0.714 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16875 | PFKFB3 | 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 | 0.849 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O43286 | B4GALT5 | Beta-1,4-galactosyltransferase 5 | 0.917 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O43451 | MGAM | Maltase-glucoamylase | 0.871 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | Q7KZN9 | COX15 | Cytochrome c oxidase assembly protein COX15 homolog | 0.764 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | 0.901 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24666 | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | -0.832 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9HCC0 | MCCC2 | Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial | -0.782 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P33121 | ACSL1 | Long-chain-fatty-acid--CoA ligase 1 | 0.886 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | Q9UHK6 | AMACR | Alpha-methylacyl-CoA racemase | -0.704 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | Q86VZ5 | SGMS1 | Phosphatidylcholine:ceramide cholinephosphotransferase 1 | -0.736 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P57054 | PIGP | Phosphatidylinositol N-acetylglucosaminyltransferase subunit P | -0.881 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9UNP4 | ST3GAL5 | Lactosylceramide alpha-2,3-sialyltransferase | -0.819 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9BX95 | SGPP1 | Sphingosine-1-phosphate phosphatase 1 | -0.743 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P32321 | DCTD | Deoxycytidylate deaminase | -0.748 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9BPW9 | DHRS9 | Dehydrogenase/reductase SDR family member 9 | 0.817 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O75911 | DHRS3 | Short-chain dehydrogenase/reductase 3 | -0.81 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9UHY7 | ENOPH1 | Enolase-phosphatase E1 | -0.737 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | 0.883 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P46976 | GYG1 | Glycogenin-1 | 0.817 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P06737 | PYGL | Glycogen phosphorylase, liver form | 0.863 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | Q9BQB6 | VKORC1 | Vitamin K epoxide reductase complex subunit 1 | 0.731 |
| Dexlansoprazole | hsa01230 | Biosynthesis of amino acids | 5.53E-03 | 2 | P15104, P37837 | GLUL, TALDO1 | More | | Dexlansoprazole | hsa01523 | Antifolate resistance | 2.54E-03 | 4 | P41440, Q92820, P04818, P01375 | SLC19A1, GGH, TYMS, TNF | More | | Dexlansoprazole | hsa01524 | Platinum drug resistance | 4.44E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Dexlansoprazole | hsa03013 | RNA transport | 4.49E-02 | 5 | P62826, Q9UBU9, P63279, P68104, Q14232 | RAN, NXF1, UBE2I, EEF1A1, EIF2B1 | More | | Dexlansoprazole | hsa03020 | RNA polymerase | 6.21E-04 | 4 | P30876, P24928, P62487, Q9Y535 | POLR2B, POLR2A, POLR2G, POLR3H | More | | Dexlansoprazole | hsa03040 | Spliceosome | 9.99E-06 | 10 | Q14562, O43143, O60508, P08579, Q13595, Q07955, Q01130, P84103, Q13243, P11142 | DHX8, DHX15, CDC40, SNRPB2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8 | More | | Dexlansoprazole | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Dexlansoprazole | hsa04012 | ErbB signaling pathway | 3.15E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | | Dexlansoprazole | hsa04014 | Ras signaling pathway | 1.07E-03 | 10 | P20827, Q9NRA1, P49767, Q13009, Q14644, P0DP23, P62873, P63218, P50151, P19174 | EFNA1, PDGFC, VEGFC, TIAM1, RASA3, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Dexlansoprazole | hsa04015 | Rap1 signaling pathway | 3.07E-02 | 4 | P25116, Q8TEU7, P08514, P17252 | F2R, RAPGEF6, ITGA2B, PRKCA | More | | Dexlansoprazole | hsa04020 | Calcium signaling pathway | 6.68E-05 | 10 | Q08828, Q16566, P30679, O15399, P0DP24, P0DP23, P05141, P51828, P23634, P49767 | ADCY1, CAMK4, GNA15, GRIN2D, CALM2, CALM1, SLC25A5, ADCY7, ATP2B4, VEGFC | More | | Dexlansoprazole | hsa04022 | cGMP-PKG signaling pathway | 4.38E-03 | 6 | P18848, P31751, Q08828, P51828, P05141, P0DP23 | ATF4, AKT2, ADCY1, ADCY7, SLC25A5, CALM1 | More | | Dexlansoprazole | hsa04024 | cAMP signaling pathway | 5.14E-04 | 9 | Q08828, P51828, P42338, P31751, P0DP24, P0DP23, P23634, Q13370, Q13009 | ADCY1, ADCY7, PIK3CB, AKT2, CALM2, CALM1, ATP2B4, PDE3B, TIAM1 | More | | Dexlansoprazole | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.16E-03 | 8 | Q8NHW4, P09341, P25024, P25025, P47992, Q9UBD3, Q13651, P01375 | CCL4L2, CXCL1, CXCR1, CXCR2, XCL1, XCL2, IL10RA, TNF | More | | Dexlansoprazole | hsa04062 | Chemokine signaling pathway | 1.59E-03 | 9 | P07948, P19174, P62873, P63218, P50151, Q13009, P14598, P42224, P25963 | LYN, PLCG1, GNB1, GNG5, GNG10, TIAM1, NCF1, STAT1, NFKBIA | More | | Dexlansoprazole | hsa04064 | NF-kappa B signaling pathway | 4.85E-04 | 11 | O00463, P14778, P01584, Q13077, Q16548, Q8WV28, P63279, P24522, Q8NHW4, P09341, Q9NQC7 | TRAF5, IL1R1, IL1B, TRAF1, BCL2A1, BLNK, UBE2I, GADD45A, CCL4L2, CXCL1, CYLD | More | | Dexlansoprazole | hsa04070 | Phosphatidylinositol signaling system | 1.13E-04 | 8 | P19174, P0DP23, P42338, O14986, P23743, Q16760, P48426, P27987 | PLCG1, CALM1, PIK3CB, PIP5K1B, DGKA, DGKD, PIP4K2A, ITPKB | More | | Dexlansoprazole | hsa04071 | Sphingolipid signaling pathway | 9.99E-04 | 5 | Q9H228, P01375, Q13510, Q13362, Q9UQC2 | EDG8, TNF, ASAH1, PPP2R5C, GAB2 | More | | Dexlansoprazole | hsa04072 | Phospholipase D signaling pathway | 2.40E-03 | 6 | P31751, O14986, Q15438, Q08828, P51828, Q16760 | AKT2, PIP5K1B, PSCD1, ADCY1, ADCY7, DGKD | More | | Dexlansoprazole | hsa04080 | Neuroactive ligand-receptor interaction | 1.40E-02 | 8 | P08311, Q15722, P21453, Q9H228, P43657, P21730, P07550, P35318 | CTSG, LTB4R, S1PR1, EDG8, P2RY5, C5AR1, ADRB2, ADM | More | | Dexlansoprazole | hsa04110 | Cell cycle | 7.05E-05 | 8 | P06493, O60566, O75293, P30304, P33981, P42773, P01106, Q13547 | CDK1, BUB1B, GADD45B, CDC25A, TTK, CDKN2C, MYC, HDAC1 | More | | Dexlansoprazole | hsa04114 | Oocyte meiosis | 3.70E-04 | 7 | P0DP24, P0DP23, Q08828, P51828, P27348, Q13362, Q14738 | CALM2, CALM1, ADCY1, ADCY7, YWHAQ, PPP2R5C, PPP2R5D | More | | Dexlansoprazole | hsa04120 | Ubiquitin mediated proteolysis | 4.82E-03 | 2 | Q9UBT2, Q14669 | SAE2, TRIP12 | More | | Dexlansoprazole | hsa04140 | Autophagy - animal | 1.71E-02 | 5 | P31751, Q7L523, O75460, Q96GC9, Q8TEV9 | AKT2, RRAGA, ERN1, TMEM49, SMCR8 | More | | Dexlansoprazole | hsa04141 | Protein processing in endoplasmic reticulum | 8.60E-03 | 6 | P30101, P60604, P11142, P08238, Q9H173, Q9UNL2 | PDIA3, UBE2G2, HSPA8, HSP90AB1, SIL1, SSR3 | More | | Dexlansoprazole | hsa04142 | Lysosome | 2.08E-03 | 6 | Q99437, P25774, P22304, Q13510, Q04900, Q9Y227 | ATP6V0B, CTSS, IDS, ASAH1, CD164, ENTPD4 | More | | Dexlansoprazole | hsa04144 | Endocytosis | 2.25E-02 | 5 | O75351, P42566, Q15438, Q14161, Q9UNH7 | VPS4B, EPS15, PSCD1, GIT2, SNX6 | More | | Dexlansoprazole | hsa04145 | Phagosome | 2.53E-03 | 8 | P11215, P14598, Q71U36, Q13509, P68371, Q13488, Q99437, P25774 | ITGAM, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1, ATP6V0B, CTSS | More | | Dexlansoprazole | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Dexlansoprazole | hsa04211 | Longevity regulating pathway | 1.88E-02 | 4 | P31751, Q08828, P51828, P18848 | AKT2, ADCY1, ADCY7, ATF4 | More | | Dexlansoprazole | hsa04213 | Longevity regulating pathway - multiple species | 4.07E-03 | 5 | P31751, Q9Y4H2, Q08828, P51828, Q13547 | AKT2, IRS2, ADCY1, ADCY7, HDAC1 | More | | Dexlansoprazole | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.71E-05 | 9 | Q08828, P51828, P31751, P18848, Q13362, Q14738, P0DP24, P0DP23, P23634 | ADCY1, ADCY7, AKT2, ATF4, PPP2R5C, PPP2R5D, CALM2, CALM1, ATP2B4 | More | | Dexlansoprazole | hsa04270 | Vascular smooth muscle contraction | 3.82E-02 | 5 | P24723, Q04759, Q14643, P22694, P35318 | PRKCH, PRKCQ, ITPR1, PRKACB, ADM | More | | Dexlansoprazole | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Dexlansoprazole | hsa04360 | Axon guidance | 1.71E-02 | 4 | P20827, O95631, P42338, P23528 | EFNA1, NTN1, PIK3CB, CFL1 | More | | Dexlansoprazole | hsa04371 | Apelin signaling pathway | 1.56E-05 | 12 | P62873, P63218, P50151, P31751, Q08828, P51828, Q13370, Q14344, Q13485, P84022, Q16566, P0DP23 | GNB1, GNG5, GNG10, AKT2, ADCY1, ADCY7, PDE3B, GNA13, SMAD4, SMAD3, CAMK4, CALM1 | More | | Dexlansoprazole | hsa04380 | Osteoclast differentiation | 5.27E-04 | 10 | Q9NQC7, Q9UQC2, Q16539, P23458, P31751, P01584, P14778, O75015, P01375, Q8N149 | CYLD, GAB2, MAPK14, JAK1, AKT2, IL1B, IL1R1, FCGR3B, TNF, LILRA2 | More | | Dexlansoprazole | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Dexlansoprazole | hsa04540 | Gap junction | 1.08E-02 | 4 | Q13509, P68371, Q71U36, Q9NRA1 | TUBB3, TUBB2C, TUBA1A, PDGFC | More | | Dexlansoprazole | hsa04610 | Complement and coagulation cascades | 4.48E-02 | 3 | P01042, P09871, P11215 | KNG1, C1S, ITGAM | More | | Dexlansoprazole | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | | Dexlansoprazole | hsa04612 | Antigen processing and presentation | 5.27E-04 | 9 | P13765, P48382, P26715, P26717, Q07444, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRC3, KLRD1, KLRC4, CD8A, TNF | More | | Dexlansoprazole | hsa04613 | Neutrophil extracellular trap formation | 1.02E-04 | 8 | P11215, Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | ITGAM, HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Dexlansoprazole | hsa04620 | Toll-like receptor signaling pathway | 2.54E-03 | 3 | P01584, P31751, Q8NHW4 | IL1B, AKT2, CCL4L2 | More | | Dexlansoprazole | hsa04623 | Cytosolic DNA-sensing pathway | 1.25E-05 | 5 | P01584, P01568, P25963, Q9Y535, Q8NHW4 | IL1B, IFNA21, NFKBIA, POLR3H, CCL4L2 | More | | Dexlansoprazole | hsa04625 | C-type lectin receptor signaling pathway | 1.14E-03 | 8 | Q9ULY5, P01584, Q9NQC7, P20749, P01375, P31751, P0DP23, Q16539 | CLEC4E, IL1B, CYLD, BCL3, TNF, AKT2, CALM1, MAPK14 | More | | Dexlansoprazole | hsa04630 | JAK-STAT signaling pathway | 4.54E-02 | 3 | P31751, P23458, Q13651 | AKT2, JAK1, IL10RA | More | | Dexlansoprazole | hsa04640 | Hematopoietic cell lineage | 2.50E-03 | 11 | P13612, P27930, P15144, P25063, P09693, P01732, P01730, P06127, P09564, P13765, P01375 | ITGA4, IL1R2, ANPEP, CD24, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF | More | | Dexlansoprazole | hsa04650 | Natural killer cell mediated cytotoxicity | 5.68E-06 | 11 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, Q07444, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC3, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P01375 | TNF | Tumor necrosis factor | -0.783 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.718 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.769 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.922 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.764 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.881 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.941 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.858 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.803 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.716 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.81 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.915 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Q07444 | KLRC3 | NKG2-E type II integral membrane protein | 0.718 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.915 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 |
| Dexlansoprazole | hsa04657 | IL-17 signaling pathway | 2.18E-04 | 6 | O00463, Q16539, P49841, P09341, P14780, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, TNF | More | | Dexlansoprazole | hsa04658 | Th1 and Th2 cell differentiation | 6.56E-09 | 15 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, P42224, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT1, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Q04759 | PRKCQ | Protein kinase C theta type | 0.869 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.761 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.881 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.731 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.762 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.708 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.769 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.767 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.75 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.821 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.878 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.858 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.795 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.734 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.702 | P30304 | CDC25A | M-phase inducer phosphatase 1 | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.721 |
| Dexlansoprazole | hsa04659 | Th17 cell differentiation | 6.61E-08 | 18 | P25963, Q04759, Q16539, P19174, P01730, P06239, P42224, P14784, P13765, P14778, P40189, Q9UL17, P23771, P84022, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, PLCG1, CD4, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL6ST, TBX21, GATA3, SMAD3, HSP90AB1, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.818 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Q04759 | PRKCQ | Protein kinase C theta type | 0.869 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.869 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.762 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.708 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.769 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.767 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | P29375 | JARID1A | Lysine-specific demethylase 5A | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.764 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.783 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.75 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.768 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.717 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.795 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.734 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.909 | P29375 | JARID1A | Lysine-specific demethylase 5A | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.83 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.858 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.878 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | -0.77 | P29375 | JARID1A | Lysine-specific demethylase 5A | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.711 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 1 | P30304 | CDC25A | M-phase inducer phosphatase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.761 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.731 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | Q92630 | DYRK2 | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.881 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 |
| Dexlansoprazole | hsa04660 | T cell receptor signaling pathway | 1.08E-04 | 15 | P01375, Q04759, O95267, Q08881, P19174, P16333, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, PLCG1, NCK1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Dexlansoprazole | hsa04664 | Fc epsilon RI signaling pathway | 7.09E-04 | 7 | P01375, P04141, Q16539, Q9UQC2, P07948, P19174, P09917 | TNF, CSF2, MAPK14, GAB2, LYN, PLCG1, ALOX5 | More | | Dexlansoprazole | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | | Dexlansoprazole | hsa04668 | TNF signaling pathway | 2.21E-02 | 5 | P01375, O00463, Q16539, P20749, P14780 | TNF, TRAF5, MAPK14, BCL3, MMP9 | More | | Dexlansoprazole | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | | Dexlansoprazole | hsa04713 | Circadian entrainment | 2.39E-03 | 6 | P0DP23, P62873, P63218, P50151, Q08828, P51828 | CALM1, GNB1, GNG5, GNG10, ADCY1, ADCY7 | More | | Dexlansoprazole | hsa04720 | Long-term potentiation | 1.95E-03 | 5 | Q16566, P0DP23, P18848, O15399, Q08828 | CAMK4, CALM1, ATF4, GRIN2D, ADCY1 | More | | Dexlansoprazole | hsa04724 | Glutamatergic synapse | 1.74E-03 | 6 | O15399, P62873, P63218, P50151, P15104, Q9NSB8 | GRIN2D, GNB1, GNG5, GNG10, GLUL, HOMER2 | More | | Dexlansoprazole | hsa04725 | Cholinergic synapse | 1.39E-02 | 4 | Q08828, P51828, P18848, P31751 | ADCY1, ADCY7, ATF4, AKT2 | More | | Dexlansoprazole | hsa04726 | Serotonergic synapse | 3.80E-02 | 4 | P62873, P63218, P50151, P09917 | GNB1, GNG5, GNG10, ALOX5 | More | | Dexlansoprazole | hsa04727 | GABAergic synapse | 4.18E-03 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Dexlansoprazole | hsa04728 | Dopaminergic synapse | 7.83E-03 | 5 | P31751, P18848, Q13362, Q14738, P0DP23 | AKT2, ATF4, PPP2R5C, PPP2R5D, CALM1 | More | | Dexlansoprazole | hsa04730 | Long-term depression | 4.86E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Dexlansoprazole | hsa04744 | Phototransduction | 9.21E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Dexlansoprazole | hsa04750 | Inflammatory mediator regulation of TRP channels | 9.86E-03 | 4 | P01584, Q08828, P51828, P0DP23 | IL1B, ADCY1, ADCY7, CALM1 | More | | Dexlansoprazole | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Dexlansoprazole | hsa04911 | Insulin secretion | 2.40E-02 | 3 | Q08828, P51828, P18848 | ADCY1, ADCY7, ATF4 | More | | Dexlansoprazole | hsa04912 | GnRH signaling pathway | 7.29E-04 | 6 | Q08828, P51828, P18848, P0DP24, P0DP23, P45985 | ADCY1, ADCY7, ATF4, CALM2, CALM1, MAP2K4 | More | | Dexlansoprazole | hsa04914 | Progesterone-mediated oocyte maturation | 3.92E-02 | 3 | P42338, Q13370, P08238 | PIK3CB, PDE3B, HSP90AB1 | More | | Dexlansoprazole | hsa04915 | Estrogen signaling pathway | 2.13E-02 | 5 | P18848, Q08828, P51828, P31751, P0DP23 | ATF4, ADCY1, ADCY7, AKT2, CALM1 | More | | Dexlansoprazole | hsa04916 | Melanogenesis | 2.40E-02 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | | Dexlansoprazole | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | | Dexlansoprazole | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Dexlansoprazole | hsa04923 | Regulation of lipolysis in adipocytes | 5.15E-03 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | | Dexlansoprazole | hsa04924 | Renin secretion | 1.94E-03 | 5 | P22694, P07550, Q14643, Q13370, P0DP23 | PRKACB, ADRB2, ITPR1, PDE3B, CALM1 | More | | Dexlansoprazole | hsa04925 | Aldosterone synthesis and secretion | 3.67E-05 | 7 | P18848, Q08828, P51828, P0DP24, P0DP23, Q16566, P23634 | ATF4, ADCY1, ADCY7, CALM2, CALM1, CAMK4, ATP2B4 | More | | Dexlansoprazole | hsa04926 | Relaxin signaling pathway | 2.46E-02 | 4 | P31751, P18848, Q08828, P51828 | AKT2, ATF4, ADCY1, ADCY7 | More | | Dexlansoprazole | hsa04927 | Cortisol synthesis and secretion | 1.59E-02 | 3 | P18848, Q08828, P51828 | ATF4, ADCY1, ADCY7 | More | | Dexlansoprazole | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Dexlansoprazole | hsa04932 | Non-alcoholic fatty liver disease | 1.04E-02 | 5 | P31751, P18848, O75460, P01584, O95298 | AKT2, ATF4, ERN1, IL1B, NDUFC2 | More | | Dexlansoprazole | hsa04934 | Cushing syndrome | 4.54E-02 | 3 | P18848, Q08828, P51828 | ATF4, ADCY1, ADCY7 | More | | Dexlansoprazole | hsa04935 | Growth hormone synthesis, secretion and action | 1.88E-02 | 4 | Q08828, P51828, P18848, P31751 | ADCY1, ADCY7, ATF4, AKT2 | More | | Dexlansoprazole | hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 2.09E-02 | 2 | P23634, P62491 | ATP2B4, RAB11A | More | | Dexlansoprazole | hsa04970 | Salivary secretion | 1.73E-05 | 5 | Q08828, P51828, P23634, P0DP24, P0DP23 | ADCY1, ADCY7, ATP2B4, CALM2, CALM1 | More | | Dexlansoprazole | hsa04971 | Gastric acid secretion | 2.54E-03 | 4 | Q08828, P51828, P15311, P0DP23 | ADCY1, ADCY7, VIL2, CALM1 | More | | Dexlansoprazole | hsa04972 | Pancreatic secretion | 4.94E-03 | 3 | P23634, P51828, P62491 | ATP2B4, ADCY7, RAB11A | More | | Dexlansoprazole | hsa04976 | Bile secretion | 7.23E-04 | 5 | Q08828, P51828, P22694, P08183, Q14032 | ADCY1, ADCY7, PRKACB, ABCB1, BAAT | More | | Dexlansoprazole | hsa05010 | Alzheimer disease | 4.94E-03 | 9 | O95298, Q00535, O75460, P0DP23, P01584, P18848, P31751, P05141, P28070 | NDUFC2, CDK5, ERN1, CALM1, IL1B, ATF4, AKT2, SLC25A5, PSMB4 | More | | Dexlansoprazole | hsa05012 | Parkinson disease | 1.77E-02 | 6 | P60604, P19174, P0DP23, Q71U36, Q13509, P68371 | UBE2G2, PLCG1, CALM1, TUBA1A, TUBB3, TUBB2C | More | | Dexlansoprazole | hsa05016 | Huntington disease | 2.24E-02 | 7 | O95298, P24928, P30876, P62487, P05141, O75460, P28070 | NDUFC2, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4 | More | | Dexlansoprazole | hsa05017 | Spinocerebellar ataxia | 3.94E-02 | 4 | O75460, P31751, P28070, P05141 | ERN1, AKT2, PSMB4, SLC25A5 | More | | Dexlansoprazole | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.67E-02 | 9 | O95298, Q8TEV9, O75460, P18848, P05141, Q00535, P01584, P0DP23, P28070 | NDUFC2, SMCR8, ERN1, ATF4, SLC25A5, CDK5, IL1B, CALM1, PSMB4 | More | | Dexlansoprazole | hsa05032 | Morphine addiction | 2.18E-02 | 4 | P62873, P63218, P50151, Q13370 | GNB1, GNG5, GNG10, PDE3B | More | | Dexlansoprazole | hsa05034 | Alcoholism | 1.53E-06 | 11 | O15399, Q16566, Q13547, P0DP23, P63218, Q93077, P58876, P62807, Q16778, O60814, P68431 | GRIN2D, CAMK4, HDAC1, CALM1, GNG5, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Dexlansoprazole | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | | Dexlansoprazole | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 6.88E-04 | 8 | Q16539, P25963, Q13488, P09341, P19174, P25024, P25025, P07948 | MAPK14, NFKBIA, TCIRG1, CXCL1, PLCG1, CXCR1, CXCR2, LYN | More | | Dexlansoprazole | hsa05130 | Pathogenic Escherichia coli infection | 3.19E-02 | 6 | Q71U36, P16333, Q13509, P68371, Q14344, P25963 | TUBA1A, NCK1, TUBB3, TUBB2C, GNA13, NFKBIA | More | | Dexlansoprazole | hsa05132 | Salmonella infection | 2.75E-02 | 7 | P25963, P08238, O75369, Q71U36, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, FLNB, TUBA1A, TUBB3, TUBB2C, VPS41 | More | | Dexlansoprazole | hsa05133 | Pertussis | 1.70E-03 | 4 | P11215, P0DP23, P23528, P09871 | ITGAM, CALM1, CFL1, C1S | More | | Dexlansoprazole | hsa05134 | Legionellosis | 4.75E-02 | 3 | P25963, P11215, P11142 | NFKBIA, ITGAM, HSPA8 | More | | Dexlansoprazole | hsa05140 | Leishmaniasis | 3.37E-03 | 9 | O75015, P14598, P11215, P42224, P13765, O60603, P25963, P49006, Q16539 | FCGR3B, NCF1, ITGAM, STAT1, HLA-DOB, TLR2, NFKBIA, MARCKSL1, MAPK14 | More | | Dexlansoprazole | hsa05144 | Malaria | 1.20E-03 | 4 | P60033, O60603, P35443, P26718 | CD81, TLR2, THBS4, KLRK1 | More | | Dexlansoprazole | hsa05146 | Amoebiasis | 8.26E-04 | 9 | P09341, P14778, P27930, P01375, O60603, P05089, P22694, P12814, P08311 | CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, ACTN1, CTSG | More | | Dexlansoprazole | hsa05150 | Staphylococcus aureus infection | 1.91E-02 | 4 | Q14532, P59665, P59666, P49913 | KRT32, DEFA1; DEFA1B, DEFA3, CAMP | More | | Dexlansoprazole | hsa05152 | Tuberculosis | 4.16E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | Dexlansoprazole | hsa05163 | Human cytomegalovirus infection | 4.22E-08 | 24 | P31751, P01375, P25963, P62873, P63218, P50151, Q14643, P0DP23, Q14344, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, P18848, P04637, O00463, P30101, P01568 | AKT2, TNF, NFKBIA, GNB1, GNG5, GNG10, ITPR1, CALM1, GNA13, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, ATF4, TP53, TRAF5, PDIA3, IFNA21 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | 0.726 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P01375 | TNF | Tumor necrosis factor | 0.732 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.818 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.82 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.703 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.704 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.728 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P0DP23 | CALM1 | Calmodulin-1 | 0.775 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P0DP23 | CALM1 | Calmodulin-1 | 0.857 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | -0.756 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.756 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.756 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.796 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P51828 | ADCY7 | Adenylate cyclase type 7 | 0.726 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.842 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.778 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P01584 | IL1B | Interleukin-1 beta | 0.735 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.786 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.889 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.861 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.78 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P18848 | ATF4 | Cyclic AMP-dependent transcription factor ATF-4 | 0.748 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P04637 | TP53 | Cellular tumor antigen p53 | -0.823 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.734 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P30101 | PDIA3 | Protein disulfide-isomerase A3 | 0.83 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P01568 | IFNA21 | Interferon alpha-21 | -0.733 |
| Dexlansoprazole | hsa05164 | Influenza A | 4.49E-02 | 5 | P31751, P01584, P23458, P05141, Q9UBU9 | AKT2, IL1B, JAK1, SLC25A5, NXF1 | More | | Dexlansoprazole | hsa05166 | Human T-cell leukemia virus 1 infection | 3.90E-02 | 7 | P23458, P05141, P62826, Q08828, P51828, P18848, P31751 | JAK1, SLC25A5, RAN, ADCY1, ADCY7, ATF4, AKT2 | More | | Dexlansoprazole | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 8.62E-05 | 10 | P01568, P42224, P25963, P62873, P63218, P50151, P19174, P07948, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GNB1, GNG5, GNG10, PLCG1, LYN, CSF2, CALM1 | More | | Dexlansoprazole | hsa05168 | Herpes simplex virus 1 infection | 2.66E-04 | 16 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, P42338, Q9Y2A4, Q13398, P51522, P17038, Q03923, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, PIK3CB, ZNF443, ZNF211, ZNF83, ZNF43, ZNF85, ZNF140, ZNF189, ZNF212 | More | | Dexlansoprazole | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | | Dexlansoprazole | hsa05170 | Human immunodeficiency virus 1 infection | 1.19E-02 | 8 | P62873, P63218, P50151, P0DP23, P30101, P01568, P25963, P19174 | GNB1, GNG5, GNG10, CALM1, PDIA3, IFNA21, NFKBIA, PLCG1 | More | | Dexlansoprazole | hsa05200 | Pathways in cancer | 2.98E-04 | 18 | P42338, P08238, P42224, P25963, P19174, P43246, P84022, P20585, P14923, P62873, P63218, P50151, Q14344, O75293, P0DP23, P01568, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, MSH2, SMAD3, MSH3, JUP, GNB1, GNG5, GNG10, GNA13, GADD45B, CALM1, IFNA21, IL2RB, IL6ST | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P29375 | JARID1A | Lysine-specific demethylase 5A | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | P29375 | JARID1A | Lysine-specific demethylase 5A | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.711 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 1 | P29375 | JARID1A | Lysine-specific demethylase 5A | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.764 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.783 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.818 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.869 | P29375 | JARID1A | Lysine-specific demethylase 5A | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.87 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.816 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | -0.77 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P20585 | MSH3 | DNA mismatch repair protein Msh3 | 0.825 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14923 | JUP | Junction plakoglobin | -0.735 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.82 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.703 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.704 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | -0.756 | P29375 | JARID1A | Lysine-specific demethylase 5A | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.748 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.742 | P29375 | JARID1A | Lysine-specific demethylase 5A | P0DP23 | CALM1 | Calmodulin-1 | 0.755 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P0DP23 | CALM1 | Calmodulin-1 | 0.775 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P01568 | IFNA21 | Interferon alpha-21 | -0.733 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.768 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.717 | P29375 | JARID1A | Lysine-specific demethylase 5A | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.83 |
| Dexlansoprazole | hsa05202 | Transcriptional misregulation in cancer | 2.87E-03 | 12 | P14780, P27930, Q15744, Q16548, P11215, P05164, P12838, P08246, Q9C0K0, Q13547, P12980, P24522 | MMP9, IL1R2, CEBPE, BCL2A1, ITGAM, MPO, DEFA4, ELA2, BCL11B, HDAC1, LYL1, GADD45A | More | | Dexlansoprazole | hsa05203 | Viral carcinogenesis | 2.10E-04 | 8 | Q12933, P42229, Q13547, Q15283, P58876, P62807, Q16778, O60814 | TRAF2, STAT5A, HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Dexlansoprazole | hsa05204 | Chemical carcinogenesis | 2.81E-05 | 4 | Q16772, P09211, P78417, P11712 | GSTA3, GSTP1, GSTO1, CYP2C9 | More | | Dexlansoprazole | hsa05205 | Proteoglycans in cancer | 4.46E-02 | 4 | Q12955, Q14247, P17252, P08962 | ANK3, CTTN, PRKCA, CD63 | More | | Dexlansoprazole | hsa05212 | Pancreatic cancer | 1.31E-04 | 7 | P42338, P31751, Q15311, P23458, P42224, P84022, O75293 | PIK3CB, AKT2, RALBP1, JAK1, STAT1, SMAD3, GADD45B | More | | Dexlansoprazole | hsa05214 | Glioma | 2.11E-03 | 4 | P0DP23, P42338, P19174, O75293 | CALM1, PIK3CB, PLCG1, GADD45B | More | | Dexlansoprazole | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Dexlansoprazole | hsa05223 | Non-small cell lung cancer | 4.24E-02 | 3 | P19174, Q9HC35, O75293 | PLCG1, EML4, GADD45B | More | | Dexlansoprazole | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Dexlansoprazole | hsa05231 | Choline metabolism in cancer | 3.32E-03 | 6 | P31751, Q9Y259, P19174, P49619, Q16760, O14986 | AKT2, CHKB, PLCG1, DGKG, DGKD, PIP5K1B | More | | Dexlansoprazole | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.47E-05 | 11 | O95267, P19174, P07766, P20963, P09693, P06239, P42224, O60603, Q16539, Q9HC35, P01730 | RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, STAT1, TLR2, MAPK14, EML4, CD4 | More | | Dexlansoprazole | hsa05310 | Asthma | 3.47E-04 | 4 | P13765, P29965, P12724, P01375 | HLA-DOB, CD40LG, RNASE3, TNF | More | | Dexlansoprazole | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Dexlansoprazole | hsa05321 | Inflammatory bowel disease | 4.38E-03 | 5 | P01375, P13765, Q14765, Q9UL17, P23771 | TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Dexlansoprazole | hsa05322 | Systemic lupus erythematosus | 5.29E-06 | 13 | O75015, P08246, P08311, P09871, P01375, P13765, Q93077, P58876, P62807, Q16778, O60814, P68431, P12814 | FCGR3B, ELA2, CTSG, C1S, TNF, HLA-DOB, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1 | More | | Dexlansoprazole | hsa05330 | Allograft rejection | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Dexlansoprazole | hsa05332 | Graft-versus-host disease | 9.99E-03 | 4 | P13765, P01375, P26715, Q13241 | HLA-DOB, TNF, KLRC1, KLRD1 | More | | Dexlansoprazole | hsa05340 | Primary immunodeficiency | 4.24E-02 | 3 | P01730, P07766, P06239 | CD4, CD3E, LCK | More | | Dexlansoprazole | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | | Dexlansoprazole | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Dexlansoprazole | hsa05418 | Fluid shear stress and atherosclerosis | 1.56E-05 | 12 | Q16539, P42338, Q14145, P14598, P10599, P14780, P01375, P04637, P14778, P27930, P0DP23, P08238 | MAPK14, PIK3CB, KEAP1, NCF1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2, CALM1, HSP90AB1 | More | | |